Back to results

Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

Primary Purpose

Neoplasm Metastasis, Gastric Cancer, Colorectal Cancer

Status

Unknown status

Phase

Phase 1

Locations

Korea, Republic of

Study Type

Interventional

Intervention

GC1118

About this trial

This is an interventional treatment trial for Neoplasm Metastasis

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Willing and able to sign a written informed consent
Nineteen (19) years of age or older
For Part A and Part C, all stage IV advanced solid cancers For Part B, stage IV of gastric cancer, colorectal cancer or other cancer
Cohort1: Metastatic CRC (K-RAS wild), No prior treatment with EGFR antibody therapeutics
Cohort2: Metastatic CRC (K-RAS wild), Progressed over EGFR antibody therapeutics
Cohort3: Advanced gastric or gastroesophageal junction cancer(EGFR++ or +++ /HER2-)
For Part A and Part C, refractory solid tumors to conventional therapy (Progressive disease during or after previous conventional therapy)
Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1
Life expectancy of greater than or equal to 3 months
Availability of a new tumor biopsy or able to obtain unstained slides of tumor within 3 years
For Part B, at least one measurable tumor mass by RECIST v1.1
Acceptable laboratory parameters
If all AEs caused by the previous anti-cancer therapies including surgery, chemotherapy and radiation therapy have recovered to CTCAE grade 1 or below (except alopecia)

Exclusion Criteria:

Has had any major surgery or any therapy within the last 4 weeks and/or not recovered from prior therapy
Has had chemotherapy, surgery or radiotherapy within the previous 4 weeks
Confirmed brain metastases
Chronic Hepatitis C or known HIV positive patients
Liver Cirrhosis or active hepatitis B virus (HBV) carrier
Clinically significant interstitial pulmonary disease
Has received prior treatment with cetuximab or anti-EGFR antibody therapy is not permitted in Part B(however, allowed in Part A and Part C)
Clinically significant cardiac disease or impaired cardiac function
Acute or subacute intestinal obstruction or Inflammatory bowel disease
Has had immunotherapy, chemotherapy or hormonal therapy prohibited as per study protocol
Has participated in any study using an investigational drug during the previous 4 weeks
Known hypersensitivity to the study drug
History of second primary malignancy within 3 years prior to starting study treatment (excluding early gastric cancer, thyroid cancer, cervical cancer or skin cancer)
Severe renal impairment
Severe hepatic impairment
Current active infection
Known KRAS-mutation for Part A and Part C, Known KRAS-mutation for Part B or BRAF matant
Medical or psychiatric illness that, in the opinion of the investigator, may affect compliance with scheduled visits
Pregnant (potentially fertile patients) or lactating women
Patients refuse to use acceptable forms of contraceptions from the time of consent through six months after the study drug administration

Sites / Locations

Seoul National University HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single group assignment

Arm Description

GC1118 recombinant human anti-EGFR antibody

Outcomes

Primary Outcome Measures

Occurrence of Dose Limiting Toxicity (DLT)

Frequency of Adverse Events

Changes in safety parameters, laboratory values, vital signs and physical examinations

Vital sign assessment will include systolic and diastolic blood pressure, heart rate, respiration rate and temperature. Laboratory values will include hematology and clinical chemistry.

Secondary Outcome Measures

Overall Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1

Disease Control Rate (DCR) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1

Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1 (Part B)

Time versus plasma concentration profiles and basic PK parameters of GC1118

Presence of Human Anti Drug Antibody

Assess whether participants develop an immune response to GC1118

Full Information

NCT ID

NCT02352571

First Posted

January 21, 2015

Last Updated

July 4, 2016

Sponsor

Green Cross Corporation

1. Study Identification

Unique Protocol Identification Number

NCT02352571

Brief Title

Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

Official Title

A Prospective, Open-label, Dose Escalation (Part A) and Cohort Expansion (Part B) Phase 1 Study to Investigate the Safety, Tolerability, and Immunogenicity and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancers

Study Type

Interventional

2. Study Status

Record Verification Date

February 2016

Overall Recruitment Status

Unknown status

Study Start Date

January 2015 (undefined)

Primary Completion Date

December 2016 (Anticipated)

Study Completion Date

June 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Green Cross Corporation

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of this study is to determine the maximum tolerated dose(MTD)/Recommended Phase 2 Dose(RP2D) and to evaluate the safety and tolerability of GC1118 when given by intravenous (IV) infusion to patients with stage IV solid tumors. The study will also evaluate pharmacokinetics, immunogenicity and antitumor effect of GC1118 and explore prognostic biomarkers and pharmacodynamic biomarkers.

Detailed Description

An open-label, single-arm, multi-center, phase 1, dose-escalation study will be conducted to define the MTD/RP2D, safety, PK, immunogenicity and antitumor activity of GC1118 in patients with refractory disease for whom no standard therapy is available. This study is in three parts: a dose escalation segment (Part A), a cohort expansion (Part B) and biweekly administration(Part C). In part A, a dose escalation schema will be applied in dose level cohorts. GC1118 will be administered weekly on Study Day 1, 8, 15, and 22 of each 28-day cycle by IV infusion. Dose escalation may occur as described in the study protocol. Once the MTD has been established during Part A, the MTD cohort will be expanded in part B. And GC1118 will be administered biweekly on Study Day 1, 15 each 28-day cycle by IV infusion in part C. Study assessments will include AE monitoring including physical examination, vital signs and clinical laboratory tests, ECG monitoring, PK analysis of serum GC1118, an assessment of potential anti-GC1118 antibody response and an exploration of potential prognostic and pharmacodynamic biomarkers. Tumor response assessments using Study Day 36 CT/MRI scans will be performed approximately five weeks after the first GC1118 dose for each patient (Part A only). Patients with evidence of disease regression (partial or complete response or stable disease by RECIST criteria) will be allowed to continue therapy at the same dose. Subsequent cycles will consist of administration of GC1118 on Day 1, 8, 15, and 22 of each 28-day cycle with tumor evaluation every other cycle (approximately every 8 weeks) in part A,B and Day 1, 15 of each 28-day cycle with tumor evaluation every other cycle (approximately every 8 weeks) in part C.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Neoplasm Metastasis, Gastric Cancer, Colorectal Cancer

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

Single group assignment

Arm Type

Experimental

Arm Description

GC1118 recombinant human anti-EGFR antibody

Intervention Type

Biological

Intervention Name(s)

GC1118

Intervention Description

For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined. For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers. For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers. Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease.

Primary Outcome Measure Information:

Title

Occurrence of Dose Limiting Toxicity (DLT)

Time Frame

Approx. 6 months

Title

Frequency of Adverse Events

Time Frame

Approx. 6 months

Title

Changes in safety parameters, laboratory values, vital signs and physical examinations

Description

Vital sign assessment will include systolic and diastolic blood pressure, heart rate, respiration rate and temperature. Laboratory values will include hematology and clinical chemistry.

Time Frame

Approx. 6 months

Secondary Outcome Measure Information:

Title

Overall Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1

Time Frame

Approx. 6 months

Title

Disease Control Rate (DCR) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1

Time Frame

Approx. 6 months

Title

Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1 (Part B)

Time Frame

Approx. 6 months

Title

Time versus plasma concentration profiles and basic PK parameters of GC1118

Time Frame

Approx. 6 months

Title

Presence of Human Anti Drug Antibody

Description

Assess whether participants develop an immune response to GC1118

Time Frame

Approx. 6 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

19 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Willing and able to sign a written informed consent Nineteen (19) years of age or older For Part A and Part C, all stage IV advanced solid cancers For Part B, stage IV of gastric cancer, colorectal cancer or other cancer Cohort1: Metastatic CRC (K-RAS wild), No prior treatment with EGFR antibody therapeutics Cohort2: Metastatic CRC (K-RAS wild), Progressed over EGFR antibody therapeutics Cohort3: Advanced gastric or gastroesophageal junction cancer(EGFR++ or +++ /HER2-) For Part A and Part C, refractory solid tumors to conventional therapy (Progressive disease during or after previous conventional therapy) Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1 Life expectancy of greater than or equal to 3 months Availability of a new tumor biopsy or able to obtain unstained slides of tumor within 3 years For Part B, at least one measurable tumor mass by RECIST v1.1 Acceptable laboratory parameters If all AEs caused by the previous anti-cancer therapies including surgery, chemotherapy and radiation therapy have recovered to CTCAE grade 1 or below (except alopecia) Exclusion Criteria: Has had any major surgery or any therapy within the last 4 weeks and/or not recovered from prior therapy Has had chemotherapy, surgery or radiotherapy within the previous 4 weeks Confirmed brain metastases Chronic Hepatitis C or known HIV positive patients Liver Cirrhosis or active hepatitis B virus (HBV) carrier Clinically significant interstitial pulmonary disease Has received prior treatment with cetuximab or anti-EGFR antibody therapy is not permitted in Part B(however, allowed in Part A and Part C) Clinically significant cardiac disease or impaired cardiac function Acute or subacute intestinal obstruction or Inflammatory bowel disease Has had immunotherapy, chemotherapy or hormonal therapy prohibited as per study protocol Has participated in any study using an investigational drug during the previous 4 weeks Known hypersensitivity to the study drug History of second primary malignancy within 3 years prior to starting study treatment (excluding early gastric cancer, thyroid cancer, cervical cancer or skin cancer) Severe renal impairment Severe hepatic impairment Current active infection Known KRAS-mutation for Part A and Part C, Known KRAS-mutation for Part B or BRAF matant Medical or psychiatric illness that, in the opinion of the investigator, may affect compliance with scheduled visits Pregnant (potentially fertile patients) or lactating women Patients refuse to use acceptable forms of contraceptions from the time of consent through six months after the study drug administration

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Ahmi Woo

Phone

+ 82 31 260 9467

butami@greencross.com

Facility Information:

Facility Name

Seoul National University Hospital

City

Seoul

ZIP/Postal Code

110-744

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Yung Jue Bang, M.D., Ph.D.

bangyj@snu.ac.kr

First Name & Middle Initial & Last Name & Degree

Yung Jue Bang, Ph.D.

12. IPD Sharing Statement

Plan to Share IPD

Undecided

Citations:

PubMed Identifier

31164456

Citation

Oh DY, Lee KW, Han SW, Kim JW, Shin JW, Jo SJ, Won J, Hahn S, Lee H, Kim WH, Bang YJ. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. Oncologist. 2019 Aug;24(8):1037-e636. doi: 10.1634/theoncologist.2019-0294. Epub 2019 Jun 4.

Results Reference

derived

Learn more about this trial

Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

We'll reach out to this number within 24 hrs